Shakouri Seyed Kazem, Razavi Zeynab, Eslamian Fariba, Sadeghi-Bazargani Homayoun, Ghaffari Samad, Babaei-Ghazani Arash
Physical Medicine and Rehabilitation Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Tabriz University of Medical Sciences, Tabriz, Iran.
Ann Rehabil Med. 2015 Apr;39(2):191-8. doi: 10.5535/arm.2015.39.2.191. Epub 2015 Apr 24.
To investigate the effect of enhanced external counterpulsation (EECP) on plasma nitric oxide (NO), Endothelin 1 (ET1), high sensitive C-reactive protein (HSCRP) and quality of life (QoL) in patients with coronary artery disease (CAD).
We conducted a pilot randomized clinical trial in order to evaluate plasma NO, ET1, HSCRP and QoL before and after twenty sessions of EECP (group A) and cardiac rehabilitation (CR, group B) in 42 patients with CAD (21 in each group).
Forty-two patients (33 male and 9 female) were included in the study. The mean age was 58.2±10 years. The mean HSCRP was 1.52±0.7 in the EECP group and it was reduced to 1.27±0.4 after intervention. The reduction in HSCRP was not statistically significant in EECP and CR groups with p=0.33 and p=0.27, respectively. There was not significant improvement of NO, ET1, and QoL in the EECP and CR groups shortly after therapy (p>0.05).
Although the short-term EECP treatment in CAD patients improved HSCRP, NO, ET1, and QoL compared with the baseline those improvements are not statistically significant. Further studies are necessary with large study groups and more sessions.
探讨增强型体外反搏(EECP)对冠心病(CAD)患者血浆一氧化氮(NO)、内皮素1(ET1)、高敏C反应蛋白(HSCRP)及生活质量(QoL)的影响。
我们进行了一项初步随机临床试验,以评估42例CAD患者(每组21例)在接受20次EECP治疗(A组)和心脏康复治疗(CR,B组)前后的血浆NO、ET1、HSCRP及生活质量。
42例患者(33例男性和9例女性)纳入研究。平均年龄为58.2±10岁。EECP组的平均HSCRP为1.52±0.7,干预后降至1.27±0.4。EECP组和CR组HSCRP的降低无统计学意义,p值分别为0.33和0.27。治疗后短期内,EECP组和CR组的NO、ET1及生活质量无显著改善(p>0.05)。
尽管CAD患者短期EECP治疗与基线相比改善了HSCRP、NO、ET1及生活质量,但这些改善无统计学意义。需要更大样本量和更多疗程的进一步研究。